Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07547878 · ClinicalTrials.gov registry record · Phase 4
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
A Phase 4 study, sponsored by Baylor Research Institute.
- Not yet
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
NCT07547878 is a Phase 4 study that has not yet begun recruiting, run by Baylor Research Institute. The registered enrollment target is 64 participants.
The verdict
NCT07547878, a Phase 4 study, has not yet begun recruiting, sponsored by Baylor Research Institute.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if starting four kidney disease medicines quickly and together (a rapid treatment approach) is safe and works well in people with type 2 diabetes and chronic kidney disease. The main questions it aims to answer are: * Is it safe to start these medicines over a short period of time? * How often do kidney function changes or high potassium levels occur? * Does this approach lower protein in the urine (a sign of kidney damage)? * How many participants are able to stay on all four medicines over 6 months? Researchers will compare this approach to usual care, where medicines are started one at a time over several months. Participants will: Be assigned by chance to either this approach or usual care Start up to four approved kidney medicines over about 8 weeks (rapid treatment approach) or follow standard care Have regular clinic visits and lab tests to check kidney function and potassium levels Be followed for about 6 months
Interventions
- DRUG Finerenone
- DRUG Semaglutide
- DRUG Enalapril
- DRUG Lotensin
- DRUG Capoten
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2026-04-30 |
| Est. Completion | 2029-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07547878
The ClinicalTrials.gov registry entry for NCT07547878 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Finerenone is the first listed.
NCT07547878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07547878 about?
NCT07547878 is a clinical study titled "Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)". The goal of this clinical trial is to learn if starting four kidney disease medicines quickly and together (a rapid treatment approach) is safe and works well in people with type 2 diabetes and chronic kidney disease. The main questions it aims to answer are: * Is it safe to start these medicines ...
What is the current status of trial NCT07547878?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2026-04-30. Estimated completion is 2029-03-31.
What interventions are being tested in trial NCT07547878?
The interventions under investigation include: Finerenone (DRUG), Semaglutide (DRUG), Enalapril (DRUG), Lotensin (DRUG), Capoten (DRUG).
Who is sponsoring clinical trial NCT07547878?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.